Enterprise Value
-13.15M
Cash
27.69M
Avg Qtr Burn
-4.202M
Short % of Float
4.90%
Insider Ownership
16.19%
Institutional Own.
23.63%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
ATRN-119 Details Solid tumor/s, Cancer | Phase 1/2 Data readout | |
Eprenetapopt (APR-246) + azacitidine Details Acute myeloid leukemia, Cancer, Myelodysplastic syndrome | Failed Discontinued | |
Eprenetapopt (APR-246) + Azacitidine Details Blood disorder, Myelodysplastic syndrome | Failed Discontinued | |
APR-548 + azacitidine Details Mutant Myelodysplastic Syndromes | Failed Discontinued |